Investigational osteoporosis drug, abaloparatide, lowers fracture risk

6 marzo 2015

Abaloparatide-SC, an injectable drug being studied for the treatment of postmenopausal osteoporosis, reduces the rate of new spinal fractures by a statistically significant 86 percent and as well as statistically significant reductions in the fracture rate at other parts of the body, a phase 3 clinical trial finds.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/IVTkSVL0aYQ/150306102556.htm

Volver